| 摘要 |
<p>The invention is concerned with a sclerostin binding agent for use in a method for treating a bone fracture in a subject, where the agent is administered to the subject in a therapeutically effective amount from about 0.5 mg/kg to about 10 mg/kg, wherein one or more administrations of the sclerostin binding agent are administered over a treatment period lasting at least two weeks.</p> |
